ISLENSK ERFDAGREINING EHF

Their core work

deCODE Genetics is an Icelandic genomics company that uses population-scale genetic data and biobank resources to understand the genetic basis of human disease. They contribute large-scale genotyping, genetic risk scoring, and biobank-linked analyses to European research consortia studying mental disorders, cardiovascular disease, and chronic pain. Their core capability is linking genetic variants to disease outcomes and drug responses using Iceland's uniquely comprehensive genealogical and health record databases.

What they specialise in

How they've shifted over time

deCODE's early H2020 involvement (2018–2020) centred on foundational capabilities — training PhD researchers in bioinformatics and contributing genetic risk data to cardiovascular-mental illness comorbidity studies. In the later period (2021–2025), their focus sharpened toward translational applications: pharmacogenomics for psychiatric drug response (REALMENT), multi-omics biomarker discovery for chronic pain comorbidities (PainFACT), and real-world data integration from eHealth systems. The trajectory shows a clear shift from broad genetic epidemiology toward precision medicine and stratified treatment approaches.

deCODE is moving toward real-world evidence and drug response prediction, making them increasingly relevant for pharmaceutical and digital health collaborations.

How they like to work

deCODE exclusively joins consortia as a participant or third party — they have never coordinated an H2020 project, acting instead as a specialist data and analytics provider. With 36 unique partners across 16 countries, they connect into large European consortia (typically 10+ partners) where their role is to supply population-scale genetic data and analysis that few other organizations can match. This makes them a high-value but non-leading partner: easy to integrate, low administrative overhead, and focused on delivering genetic insights.

deCODE has collaborated with 36 distinct partners across 16 countries through just 4 projects, reflecting their integration into broad European health research networks. Their reach spans Scandinavia, Western Europe, and beyond, consistent with Nordic biobank and registry research ecosystems.

What sets them apart

deCODE Genetics holds one of the world's most comprehensive population-scale genetic databases, built from Iceland's uniquely homogeneous and well-documented population. This gives them an unmatched ability to link genotypes to phenotypes across entire disease spectra — a resource no consortium partner can easily replicate. For any project needing validated genetic risk scores, pharmacogenomic data, or biobank-linked multi-omics, deCODE is among the strongest specialist partners in Europe.

Highlights from their portfolio

• REALMENT
  Directly targets precision psychiatry by integrating eHealth, biobank, and clinical trial data to predict individual drug response in schizophrenia and mood disorders — the most translational of their projects.
• CoMorMent
  Their largest funded project (EUR 818,750) investigating why mental illness and cardiovascular disease co-occur, combining genetic, lifestyle, and registry data across a major European consortium.
• PainFACT
  Bridges chronic pain, psychiatric, and cardiovascular research using multi-omics (proteomics, metabolomics, brain imaging, genetics) — an unusually broad molecular approach to comorbidity.